	Application No.	Applicant(s)
Notice of Allowability	09/899,186	NARA ET AL.
	Examiner	Art Unit
	Raymond Covington	1625
The MAILING DATE of this communication apperature All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this app or other appropriate communication GHTS. This application is subject to	olication. If not included will be mailed in due course. THIS
1. This communication is responsive to <u>10/10/03</u> .		
2. The allowed claim(s) is/are <u>1-26</u> .	•	
3. The drawings filed on are accepted by the Examiner	:	
 4. ☐ Acknowledgment is made of a claim for foreign priority un a) ☐ All b) ☐ Some* c) ☐ None of the: 1. ☐ Certified copies of the priority documents have 2. ☐ Certified copies of the priority documents have 3. ☐ Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" onoted below. Failure to timely comply will result in ABANDONMITHIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 	been received. been received in Application No cuments have been received in this r	national stage application from the
5. A SUBSTITUTE OATH OR DECLARATION must be submit INFORMAL PATENT APPLICATION (PTO-152) which give	tted. Note the attached EXAMINER's s reason(s) why the oath or declarat	S AMENDMENT or NOTICE OF ion is deficient.
6. CORRECTED DRAWINGS (as "replacement sheets") must	t be submitted.	
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		,
(b) including changes required by the attached Examiner's Paper No./Mail Date	Amendment / Comment or in the Of	ffice action of
Identifying indicia such as the application number (see 37 CFR 1. each sheet. Replacement sheet(s) should be labeled as such in the	84(c)) should be written on the drawing the header according to 37 CFR 1 121(d	gs in the front (not the back) of
 DEPOSIT OF and/or INFORMATION about the depose attached Examiner's comment regarding REQUIREMENT F 	sit of BIOLOGICAL MATERIAL m	nust be submitted. Note the
Attachment(s) 1. ☐ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)	 5. ☐ Notice of Informal Pa 6. ☑ Interview Summary (atent Application (PTO-152)
3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/08	Paper No./Mail Date	Paper No./Mail Date <u>11</u> . 7. Examiner's Amendment/Comment
Paper No./Mail Date4. ☐ Examiner's Comment Regarding Requirement for Deposit	8. ⊠ Examiner's Statemer	nt of Reasons for Allowance
of Biological Material	9. Other	2. Fragosiio ioi / litowalioe

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Lawrence Perry on March 4, 2003.

The application has been amended and Claim 1 has been rewritten, as follows:

(Currently Amended) A piperidine derivative represented by formula (1): 1.

$$O_2N$$

$$R^2$$

$$X (CH_2)_mR^3$$

wherein;

m represents an integer of 0 to 5,

Rl and R2 independently represent a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted lower alkenyl group, a substituted or unsubstituted lower alkynyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted heterocyclic group;

R3 represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted ary1 group, or a substituted or unsubstituted heterocyclic group; and

X represents a bond or CO;

or a pharmaceutically acceptable salt thereof,

wherein the heterocyclic groups in Rl, R2 and R3 independently represent benzopyranyl, 1,4-benzodioxanyl, 1,3-benzodioxolyl, furyl, imidazolyl, imidazothiazolyl, indolyl, piperidyl, piperazinyl, pyridyl, pyridyl N-oxide, pyrazolinyl, pyrazolyl, thiadiazolyl, thienyl.

Application/Control Number: 09/899,186

Art Unit: 1625

The following is an examiner's statement of reasons for allowance: In light of the amendment by applicants and the examiner's amendment set forth herein above the rejection under 35 USC 112 has been overcome. Further, the claims as so amended are neither taught nor disclosed by the prior art.

Accordingly, claims 1-26 are allowed.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Raymond Covington whose telephone number is (703) 308-4704. The examiner can normally be reached on M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, J. McKane can be reached on (571) 272-0699. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1625

Information regarding the status of an application may be obtained from the

published applications may be obtained from either Private PAIR or Public PAIR.

Patent Application Information Retrieval (PAIR) system. Status information for

Status information for unpublished applications is available through Private PAIR

only. For more information about the PAIR system, see http://pair-

direct.uspto.gov. Should you have questions on access to the Private PAIR system,

contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Raymond Covington

Examiner

Art Unit 1625

//T RKC

RITA DESAI PRIMARY EXAMINER